CEL-SCI Corporation
503 articles about CEL-SCI Corporation
-
CEL-SCI Granted European Patent For Multikine Cancer Immunotherapy In Combination With Radiation And/Or Chemotherapy
7/11/2016
-
CEL-SCI Reports Monthly Patient Enrollment In June For Its Phase III Head And Neck Cancer Trial
7/5/2016
-
CEL-SCI Reports Monthly Patient Enrollment In May For Its Phase III Head And Neck Cancer Trial
6/1/2016
-
CEL-SCI To Present At The Fifth Annual Marcum MicroCap Conference
5/31/2016
-
CEL-SCI Announces The Closing Of Its $5 Million Registered Direct Offering
5/24/2016
-
CEL-SCI Announces $5 Million Registered Direct Offering
5/18/2016
-
CEL-SCI Reports Second Quarter Fiscal Year 2016 Financial Results
5/11/2016
-
CEL-SCI Reports Record Monthly Patient Enrollment In April For Its Phase III Head And Neck Cancer Trial
5/2/2016
-
CEL-SCI Featured On The Redchip Money Report Airing On Newsmax TV
4/8/2016
-
CEL-SCI Reports Monthly Patient Enrollment In March For Its Phase III Head And Neck Cancer Trial
4/1/2016
-
CEL-SCI Reports Monthly Patient Enrollment In February For Its Phase III Head And Neck Cancer Trial
3/1/2016
-
CEO Geert Kersten Summarizes CEL-SCI's Phase III Cancer Immunotherapy Progress In A New Video Interview
2/23/2016
-
CEL-SCI CEO Geert Kersten Was a Featured Guest On Fox Business' Making Money With Charles Payne
2/18/2016
-
CEL-SCI Reports First Quarter Fiscal 2016 Financial Results
2/10/2016
-
CEL-SCI To Present At Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference
2/8/2016
-
CEL-SCI To Present At 18th Annual BIO CEO & Investor Conference
2/3/2016
-
CEL-SCI Reports Monthly Patient Enrollment In January For Its Phase III Head And Neck Cancer Trial
2/1/2016
-
CEL-SCI’s Chief Scientific Officer Discusses Cancer Immunotherapy Multikine
1/25/2016
-
CEL-SCI’s Chief Scientific Officer Discusses Cancer Immunotherapy Multikine
1/25/2016
-
CEL-SCI To Present At The Noble Financial Capital Markets’ 12th Annual Investor Conference
1/14/2016